Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12...6364656667686970717273...8687»
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Clinical, Journal:  Persistence of Denosumab Terapy among Patients with Osteoporosis. (Pubmed Central) -  Jan 18, 2020   
    The reasons for non-persistence of denosumab therapy were transfer to another hospital (n=13), interruption of outpatient visits (n=11), dental treatment (n=4), adverse events (n=2), and patient request (n=1). Persistence was significantly lower in patients aged ≥80 years than in patients of other ages, and strategies promoting persistence are needed for these elderly patients.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Review, Journal:  Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. (Pubmed Central) -  Jan 17, 2020   
    Agents that prevent bone resorption, such as bisphosphonates or denosumab, can reduce the risk of skeletal-related events and are widely used in patients with osteoporosis or bone metastases of cancer...Dentists, as part of a multiprofessional team, have a critical role in preventing MRONJ. This review describes the incidence and pathophysiology of MRONJ and provides guidance for dental practitioners with regard to the screening, prophylactic treatment, diagnosis, and management of patients with this condition.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Review, Journal:  Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review. (Pubmed Central) -  Jan 16, 2020   
    A wide range of medications classified as tyrosine kinase inhibitors, monoclonal antibodies, mammalian target of rapamycin inhibitors, radiopharmaceuticals, selective estrogen receptor modulators, and immunosuppressants have been implicated in MRONJ. It remains crucial that oral health care providers are aware of these new medications and their associated risks to manage their patients appropriately.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg., Asahi Kasei
    Retrospective data, Journal:  Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study. (Pubmed Central) -  Jan 15, 2020   
    The median use of zoledronic acid for the presence of osteonecrosis was 25 months (15-49 months) and for Denosumab it was 16 months (11-35 months), without finding significant differences between the use of drugs p = 0.511 and the risk of osteonecrosis. Drug-induced osteonecrosis has a low incidence in Mexican population, denosumab does not show a greater number of cases of osteonecrosis compared to bisphosphonates; no association was found between functional status, number of metastatic bone sites, nor use of antigenic or tyrosine kinase inhibitors as factor associated with osteonecrosis of the jaws.
  • ||||||||||  Prolia (denosumab) / Amgen
    Enrollment open, Trial completion date, Trial primary completion date:  HDENO: Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease (clinicaltrials.gov) -  Jan 9, 2020   
    P4,  N=30, Recruiting, 
    The presence of adequate anterior cortical bone could prevent acute vertebral collapse after DT. Not yet recruiting --> Recruiting | Trial completion date: Mar 2019 --> May 2023 | Trial primary completion date: Mar 2019 --> May 2020
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion:  DENOCINA: Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. (clinicaltrials.gov) -  Jan 9, 2020   
    P3,  N=46, Completed, 
    Not yet recruiting --> Recruiting | Trial completion date: Mar 2019 --> May 2023 | Trial primary completion date: Mar 2019 --> May 2020 Active, not recruiting --> Completed
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Review, Journal:  Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. (Pubmed Central) -  Jan 4, 2020   
    There is a positive clinical response in terms of pain relief with decrease on the morbidity of surgical procedures to be performed. Finally, oncological outcomes are disparate with neither effect on metastatic disease nor local recurrence rates.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Xofigo (radium Ra-223 dichloride) / Bayer
    Journal:  Interventional treatments for metastatic bone cancer pain. (Pubmed Central) -  Jan 4, 2020   
    A fourth step in the cancer pain ladder has been proposed to include interventional approaches to cancer pain management. This review will discuss opioid therapy, radium-223, denosumab and bisphosphonate therapy, but will primarily review the available interventional treatment options for metastatic bone cancer pain.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, docetaxel / Generic mfg.
    Docetaxel + ADT + Denosumab (Twitter) -  Jan 3, 2020   
  • ||||||||||  Prolia (denosumab) / Amgen
    Trial completion date, Trial primary completion date:  Denosumab Safety Assessment in Multiple Observational Databases (clinicaltrials.gov) -  Jan 2, 2020   
    P=N/A,  N=508215, Active, not recruiting, 
    This review will discuss opioid therapy, radium-223, denosumab and bisphosphonate therapy, but will primarily review the available interventional treatment options for metastatic bone cancer pain. Trial completion date: Jun 2023 --> May 2020 | Trial primary completion date: Jun 2023 --> May 2020
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche
    Journal:  Review and update on drugs related to the development of osteonecrosis of the jaw. (Pubmed Central) -  Jan 2, 2020   
    No effective therapy is currently known for the treatment of ONJ. Therefore, in order to prevent new cases of MRONJ, it is essential for all oral healthcare professionals to be fully up-to-date with the etiopathogenic aspects of this pathology and to be aware of those drugs considered to be a risk.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Clinical, Journal:  Management of an aggressive giant cell granuloma of the mandible with denosumab: a case report. (Pubmed Central) -  Jan 1, 2020   
    Based on assumptions regarding cell type and receptors, multiple pharmacological adjuncts have been used to manage them. We describe the use of denosumab, which was successfully used as a single method of treatment, suggesting that it may be a viable alternative or adjunct to operation on giant cell granulomas of the jaws.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    @Amgen @XGEVA_com (Twitter) -  Jan 1, 2020   
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Journal:  Unique Experience of Cherubism Targeted Therapy (Pubmed Central) -  Jan 1, 2020   
    Inoperable and early stages of cherubism require a combined treatment which includes a course of monoclonal antibodies followed by alendronic acid therapy that increases osteoblasts survival. After the treatment, if it is necessary to improve the appearance, contouring surgery of excessive bone tissue is performed.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Journal:  Myeloma bone disease: from biology findings to treatment approaches. (Pubmed Central) -  Dec 29, 2019   
    Denosumab is a novel alternative to bisphosphonates against myeloma bone disease. Special considerations on this constantly evolving field are thoroughly discussed.
  • ||||||||||  bortezomib / J&J, Generic mfg., Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Clinical, Review, Journal:  Pain Management in Patients with Multiple Myeloma: An Update. (Pubmed Central) -  Dec 25, 2019   
    In this review, non-pain specialists will find an overview including a detailed description of physiopathological mechanisms underlying central sensitization and pain chronification in bone pain, the rationale for the correct use of analgesics and invasive techniques in different pain syndromes, and the most recent recommendations published on these topics. The ultimate target of this review was to underlie that different types of pain can be observed in MM patients, and highlight that only after an accurate pain assessment, clinical examination, and pain classification, can pain be safely and effectively addressed by selecting the right analgesic option for the right patient.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Journal:  Different Targeting Strategies For Treating Breast Cancer Bone Metastases. (Pubmed Central) -  Dec 24, 2019   
    A deeper understanding of these metastatic pathways can provide oncology researchers with novel avenues for treating bone metastasis, one of the main challenges to cure breast cancer. The restoration of healthy bone environment will not only improve the patient's quality of life but also reduces the tumor burden.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Review, Journal:  The RANK-RANKL axis: an opportunity for drug repurposing in cancer? (Pubmed Central) -  Dec 23, 2019   
    Here, we review the role of RANK/RANKL in tumourigenesis, including effects on tumour initiation, progression and metastasis and consider the impact of RANK/RANKL on tumour immunology and immune evasion. Finally, we look briefly at ongoing trials and future opportunities for therapeutic synergy when combining denosumab with anti-cancer agents such as immune checkpoint inhibitors.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Journal:  Aneurysmal Bone Cyst: A Review of Management. (Pubmed Central) -  Dec 23, 2019   
    Medical management with bisphosphonates (BPs) or denosumab has also been advocated...SAE is used as a pre-operative procedure to reduce intra-operative bleeding in the case of large lesions and as primary treatment for spinal lesions. The purpose of this review is to present currently available options for the management of aneurysmal bone cyst.